We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Bedside Test Predicts Sepsis with Over 90% Accuracy

By LabMedica International staff writers
Posted on 28 May 2025

Sepsis is a severe response to an infection that causes the immune system to attack the body's own organs and tissues, potentially leading to organ failure and death if not addressed promptly. More...

It is responsible for approximately 20% of all global deaths. Predicting sepsis remains challenging, as its early symptoms are vague and current diagnostic tests can take up to 18 hours, often requiring specialized labs. This delay in treatment increases the risk of death by nearly 8% per hour. Now, researchers have developed a new blood test and portable device that can detect the onset of sepsis more quickly and accurately than existing methods.

The test, developed by scientists at the University of British Columbia (UBC, Vancouver, BC, Canada) and Sepset Biosciences (Victoria, BC, Canada), has demonstrated over 90% accuracy in identifying individuals at high risk of developing sepsis, marking a significant advancement in how doctors will diagnose and treat this condition. The study, published in Nature Communications, involved analyzing blood samples from more than 3,000 hospital patients with suspected sepsis. Using machine learning, the researchers identified a six-gene expression signature, dubbed "Sepset," which successfully predicted sepsis nine times out of ten, even before a formal diagnosis was made. When tested with an additional 248 blood samples using RT-PCR (Reverse Transcription Polymerase Chain Reaction), a common hospital laboratory technique, the test showed 94% accuracy in detecting early-stage sepsis in patients whose condition was likely to worsen.

This success highlights the powerful role of AI in handling complex data, pinpointing the critical genes necessary for predicting sepsis, and developing a highly accurate algorithm for assessing sepsis risk. To make this test more accessible in clinical settings, the National Research Council of Canada (NRC) has developed a portable device, PowerBlade, which uses a drop of blood and an automated sequence of steps to detect sepsis efficiently. In trials with 30 patients, PowerBlade demonstrated 92% accuracy in identifying patients at high risk of sepsis and 89% accuracy in ruling out those not at risk. The device provided results in under three hours, making it suitable for use in various environments, including emergency rooms and remote healthcare settings.

“Sepsis accounts for roughly 20% of all global deaths,” said lead author Dr. Claudia dos Santos, a critical care physician and scientist at St. Michael’s Hospital. “Our test could be a powerful game changer, allowing physicians to quickly identify and treat patients before they begin to rapidly deteriorate.”

Related Links:
UBC
Sepset Biosciences


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Biochemical Analyzer
iBC 900
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.